Comparative

Human disease

obsessive-compulsive disorder

MONDO:0008114

Mondo defines it as: “A disorder characterized by the presence of persistent and recurrent irrational thoughts (obsessions), resulting in marked anxiety and repetitive excessive behaviors (compulsions) as a way to try to decrease that anxiety.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
1530 Compulsive disorder OMIA's OMIM numbers 1 Human disease 34.0

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Open Targets links none of these groups' human genes to this disease.

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Clomipramine None of these genes Approved
Fluoxetine None of these genes Approved
Fluvoxamine None of these genes Approved
Paroxetine None of these genes Approved
Sertraline None of these genes Approved
Cycloserine None of these genes Phase 3
Escitalopram None of these genes Phase 3
Human Immunoglobulin G None of these genes Phase 3
Memantine None of these genes Phase 3
Quetiapine None of these genes Phase 3
Serotonin None of these genes Phase 3
Topiramate None of these genes Phase 3
Troriluzole None of these genes Phase 3
Levetiracetam None of these genes Phase 2/3
Tolcapone None of these genes Phase 2/3
Acetylcysteine None of these genes Phase 2
Agomelatine None of these genes Phase 2
Aripiprazole None of these genes Phase 2
Aticaprant None of these genes Phase 2
Azithromycin None of these genes Phase 2
Bitopertin None of these genes Phase 2
Cannabidiol None of these genes Phase 2
Celecoxib None of these genes Phase 2
Dextromethorphan None of these genes Phase 2
Dronabinol None of these genes Phase 2
Flumazenil None of these genes Phase 2
Ketamine None of these genes Phase 2
Mavoglurant None of these genes Phase 2
Methamphetamine None of these genes Phase 2
Midazolam None of these genes Phase 2
Midomafetamine None of these genes Phase 2
Minocycline None of these genes Phase 2
Naltrexone None of these genes Phase 2
Nitrogen None of these genes Phase 2
Nitrous Oxide None of these genes Phase 2
Ondansetron None of these genes Phase 2
Oxytocin None of these genes Phase 2
Paliperidone None of these genes Phase 2
Penicillin G None of these genes Phase 2
Pramipexole None of these genes Phase 2
Psilocybin None of these genes Phase 2
Riluzole None of these genes Phase 2
Risperidone None of these genes Phase 2
Rituximab None of these genes Phase 2
Sarcosine None of these genes Phase 2
Secretin None of these genes Phase 2
St. John'S Wort None of these genes Phase 2
Valbenazine None of these genes Phase 2
Venlafaxine None of these genes Phase 2
Xenon None of these genes Phase 2
Nabilone None of these genes Phase 1/2
Lorazepam None of these genes Phase 1
Acamprosate None of these genes Unknown
Caffeine None of these genes Unknown
Citalopram None of these genes Unknown
Dextroamphetamine None of these genes Unknown
Duloxetine None of these genes Unknown
Esketamine None of these genes Unknown
Glycine None of these genes Unknown
Olive Oil None of these genes Unknown
Omega-3 Fatty Acids None of these genes Unknown
Pyridoxine None of these genes Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.